Rituximab (Mabthera)

DRUG3 trials

Sponsors

Ostfold Hospital Trust, Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC), Shereen Medhat Mohammed Elsayed Nassar

Conditions

CIDPHypersenstivity PneumonitisILDImmune Thrombocytopenia (ITP)

Phase 2

Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity Pneumonitis

CompletedNCT07035561

Shereen Medhat Mohammed Elsayed NassarHypersenstivity Pneumonitis, ILD

Start: 2023-06-01End: 2025-01-31Updated: 2025-06-25

Phase 3

Rituximab as Second Line Treatment for ITP

CompletedNCT00344149

Ostfold Hospital TrustImmune Thrombocytopenia (ITP)

Start: 2006-06-30End: 2014-03-31Updated: 2014-03-26

Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

RecruitingNCT06714838

Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC)CIDP

Start: 2024-10-16End: 2028-10-31Target: 100Updated: 2024-12-04

Related Papers

Rituximab therapy in patients with treatment-refractory hypersensitivity pneumonitis.

2025-10-17

Validation of Differentially Expressed Micrornas in Primary Immune Thrombocytopenia Suggests Mir-199a-5p Is a Potential Diagnostic Biomarker

Blood2023-11-021 citations

Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.

2015-02-05145 citations